（文章来源：证券日报） 证券日报网讯 12月16日，乐普医疗在互动平台回答投资者提问时表示，公司于2025年12月5日发布《关 于不向下修正"乐普转2"转股价格的公告》，公司董事会决定本次不向下修正"乐普转2"转股价格，且自 董事会审议通过次日起至"乐普转2"存续期结束（即2025年12月6日至2026年3月29日），如再次触发"乐 普转2"转股价格向下修正条款，亦不提出向下修正方案。股票价格受到宏观经济、行业周期及市场情绪 等多重因素影响，敬请投资者注意投资风险。公司目前经营正常，现金流状况良好，并拥有充足的银行 授信额度等融资渠道，完全具备到期偿还债务的能力。 ...

新华财经北京12月8日电（王菁）债市周一（12月8日）延续弱势盘整，超长端依旧领跌，银行间现券收 益率普遍走高2BPs左右，国债期货主力全线收跌；公开市场单日净投放147亿元，短期资金利率转为上 行。 机构认为，超长债的调整风险或尚未完全释放，当前供需矛盾较为突出，利差存在走阔的必要性，且当 前利差水平距高位仍有差距。 【行情跟踪】 国债期货收盘多数下跌，30年期主力合约跌0.29%报112.24，10年期主力合约涨0.02%报107.91，5年期 主力合约跌0.01%报105.745，2年期主力合约持平于102.412。 银行间主要利率债收益率普遍上行，30年期国债"25超长特别国债06"收益率上行1.75BP报2.269%， 50 年期国债"25超长特别国债03"收益率上行3.9BPs报2.415%，10年期国开债"25国开15"收益率上行1.5BP 报1.94%。 中证转债指数收盘上涨0.40%，报483.93点，成交金额603.95亿元。瑞达转债、再22转债、集智转债、 中能转债、大中转债涨幅居前，分别涨13.49%、11.49%、8.45%、8.29%、7.98%。能辉转债、乐普转 2、鹰19转债、 ...

Group 1 - Shareholders of Oujing Technology plan to reduce their holdings by no more than 3% of the company's shares [1] - Shareholders of Mingxin Xuteng also intend to collectively reduce their holdings by no more than 3% of the company's shares [1] - The actual controller of Guolian Aviation has lifted the lien on the company [1] Group 2 - Daotong Technology has received a warning letter due to undisclosed related party fund occupation and undisclosed concerted action among the top ten shareholders [1] - The company failed to disclose changes in related transactions, related party fund occupation, and the concerted action relationship between shareholder Li Hong and Xuan Yuan Ke Xin No. 46 Private Securities Investment Fund [1] - The shareholder meeting documents did not record the deliberation process and key points of discussion [1] Group 3 - Huamao Convertible Bonds will not be forcibly redeemed [2] - Le Pu Convertible Bonds 2 and Changhong Convertible Bonds will not undergo a downward adjustment [2] - Maolai Convertible Bonds are set to be listed on December 10 [2] Group 4 - Various convertible bonds have been listed with their current prices, strong redemption prices, last trading days, last conversion days, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [4] - For example, Hongfa Convertible Bonds have a current price of 127.959, a strong redemption price of 100.222, and a remaining scale of 1.922 billion [4] Group 5 - Several convertible bonds are approaching their strong redemption dates, with specific days remaining and their respective current prices and conversion values listed [7] - For instance, Hu Gong Convertible Bonds have 2 days remaining until strong redemption, with a current price of 139.840 and a conversion value of 141.02 [7]

每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 截至发稿，乐普医疗市值为292亿元。 每经AI快讯，乐普医疗（SZ 300003，收盘价：15.83元）12月5日晚间发布公告称，公司第六届第十九 次董事会会议于2025年12月5日在北京市昌平区超前路37号公司会议室以现场及通讯相结合的方式召 开，会议审议通过了《关于不向下修正"乐普转2"转股价格》的议案。 2025年1至6月份，乐普医疗的营业收入构成为：医疗器械占比52.72%，药品占比33.16%，医疗服务及 健康管理占比14.11%。 （记者 贾运可） ...

Core Viewpoint - Lepu Medical announced that from November 16 to November 28, 2025, its stock closing price has been below 80% of the current conversion price for 10 trading days, which may trigger the downward adjustment condition for the "Lepu Convertible Bonds" conversion price [1] Summary by Sections - Stock Performance - The company's stock closing price has been below 22.29 yuan per share, which is 80% of the current conversion price [1] - Corporate Actions - If the adjustment condition is triggered, the company will hold a board meeting on the triggering date to decide whether to adjust the conversion price and will fulfill its information disclosure obligations promptly [1]

Core Viewpoint - Lepu Medical announced an adjustment to the conversion price of its bonds, increasing from RMB 27.63 per share to RMB 27.86 per share, effective from November 3, 2025 [1] Group 1 - The bond is referred to as Lepu Convertible Bond 2 [1] - The adjustment in the conversion price reflects a change in the company's financial strategy [1]

Group 1 - The company announced that it will not lower the conversion price of "Lepu Convertible Bonds 2" during the upcoming two-month period from September 16, 2025, to November 15, 2025 [2] - The board of directors will reconvene after November 16, 2025, to decide on any future adjustments to the conversion price if the relevant conditions are triggered again [2] - The decision reflects the company's strategy to maintain the current conversion price without adjustments for the specified period [2]

Report Industry Investment Rating - The industry rating is "Overweight", indicating an expected increase of over 10% compared to the benchmark index in the next 6 - 12 months [27] Core Viewpoints - The current adjustment of convertible bonds still harbors potential investment opportunities. After the valuation pressure of some high - price/equity - like convertible bonds is cleared, they may offer returns to investors. The market's equity nature is stronger than its debt nature. Amid the strong performance of the equity market this year, the reversal of enhanced products may be a key factor influencing the configuration sentiment of the liability side. It is recommended to respond actively based on the actual participation time of subscription funds and the ability to withstand drawdowns [6][23] Summary by Directory When "Fear of High Prices" Meets Equity Resonance - On August 27, the convertible bond market adjusted, with the CSI Convertible Bond Index closing at 476.94, a decline of 2.82%. The declines of the Guozheng 2000 and the Equal - weighted Index of Convertible Bond Underlying Stocks were 2.01% and 2.44% respectively, while the ChiNext 50 Index rose 0.13%. There was no obvious differentiation in the structure [6][10] - The reasons for the adjustment include: directly, the rapid decline of convertible bond ETFs in the afternoon might have triggered investors' judgment of the market; in the equity market, industry performance was more differentiated, and some investors focused on the logic of switching between high - and low - value stocks or small - and large - cap stocks; actively, the long - standing "fear of high prices" in the convertible bond market led to the adjustment when the price reached a critical level [6][13][16] - The logic of the internal supply - demand mismatch in convertible bonds remains unchanged. The overall scale of the convertible bond market may continue to shrink, and there is a short - term demand gap. The logic of the equity market rally driven by incremental funds has not reversed, and there is still support from the underlying stocks for convertible bonds [6][20][21] Which Convertible Bond Varieties Are Oversold? - In the bullish equity market, it is recommended to diversify across multiple themes, such as consumer electronics, T - chain robots, chemical products, domestic computing power chips, and innovative drugs [7][25] - Pay attention to convertible bond elastic varieties and appropriately relax the drawdown limit. High - volatility products attract incremental funds during market transitions, so focus on elastic varieties with reasonable prices and cost - effectiveness [7][25] - With increased fluctuations in clause games and enhanced market pricing efficiency, keep an eye on individual bond clause changes, including high - price, low - premium convertible bonds with arbitrage opportunities and those approaching maturity with conversion incentives [7][25] - Look for oversold convertible bond varieties, including those that have declined more than the average of underlying stocks and convertible bonds, and those with significant valuation compression [7][25] - Low - price convertible bonds with improving fundamentals still have cost - effectiveness, such as Shouhua Convertible Bonds and Lepu Convertible Bonds 2 [7][25]

Key Points - On May 23, 2025, Lepu Medical (300003) closed at 11.23 yuan, up 0.45%, with a turnover rate of 0.86%, trading volume of 138,700 shares, and a transaction amount of 157 million yuan [1] - The fund flow on May 23 showed a net outflow of 6.2838 million yuan from institutional investors, a net outflow of 913,300 yuan from retail investors, while individual investors had a net inflow of 7.1971 million yuan [1][4] Company Announcements - Lepu Medical issued the fifth notice regarding the repurchase of "Lepu Convertible Bonds 2" (乐普转2), with a repurchase price set at 100.242 yuan per bond (including interest and tax). The repurchase period is from May 19, 2025, to May 23, 2025. The funds will be credited to the issuer on May 28, 2025, with the payment date for repurchase funds on May 29, 2025, and the date for investors to receive repurchase funds on May 30, 2025. It is important to note that during the repurchase period, "Lepu Convertible Bonds 2" will stop converting into shares, but the repurchase is not mandatory. Holders of "Lepu Convertible Bonds 2" can choose to repurchase part or all of their unconverted bonds [1][4] - The company also announced the resumption of the conversion of "Lepu Convertible Bonds 2," with the conversion period from October 8, 2021, to March 29, 2026. The suspension of conversion will occur from May 19, 2025, to May 23, 2025, and conversion will resume on May 26, 2025. This suspension is due to the company's stock price being below 70% of the conversion price for thirty consecutive trading days, triggering the conditional repurchase clause [2]

Core Viewpoint - The company announced a temporary suspension of the conversion of its convertible bonds "乐普转2" during the repurchase period, which is set to last from May 19, 2025, to May 23, 2025, due to specific conditions being met for the bondholders to exercise their repurchase rights [1][2]. Group 1 - The company issued 16.38 billion yuan worth of convertible bonds on March 30, 2021, with a face value of 100 yuan per bond, totaling 16.38 million bonds [1]. - The conversion period for "乐普转2" is from October 8, 2021, until the stock price falls below 70% of the conversion price of 27.92 yuan per share for thirty consecutive trading days [1]. - The company held a bondholders' meeting on May 15, 2025, to approve changes to the use of raised funds, activating the additional repurchase clause for "乐普转2" [2]. Group 2 - The suspension of the conversion of "乐普转2" will last for five trading days, starting from May 19, 2025, and will resume on May 26, 2025 [2]. - During the suspension period, the convertible bonds will continue to trade normally [2].